{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Matt Stevenson, Andrew Metry & Michael Messenger.

Matt Stevenson ^1,*, Andrew Metry ¹, Michael Messenger ^2,3

¹ School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
² Personalised Medicine and Health, University of Leeds, Leeds, UK
³ NIHR Leeds Medtech and In Vitro Diagnostics Co-operative, Leeds, UK
^* Corresponding author Email: m.d.stevenson@sheffield.ac.uk

Declared competing interests of authors: Matt Stevenson reports that he is part of a team that has received funding from Roche Diagnostics (Basel, Switzerland) in the area of biomarkers following head trauma. Michael Messenger reports that he has been a paid expert advisor to Cepheid, Inc. (Sunnyvale, CA, USA) on the development of its cancer test portfolio; he is a partner of Roche Diagnostics, with current collaborations in the field of early cancer detection and diagnosis; he is a partner of SomaLogic, Inc. (Boulder, CO, USA), with current collaborations funded by them in the field of personalised health management of pre-diabetes; he has received in-kind co-funding from Abbott Laboratories (Chicago, IL, USA) on a kidney research project; Siemens Healthineers (Erlangen, Germany) hold the pathology contract for Leeds Teaching Hospitals NHS Trust, where he holds an honorary contract of employment; and Avacta Life Sciences Limited (Wetherby, UK) is a spin-out company of the University of Leeds. All of these companies listed are working in the field of coronavirus disease 2019 (COVID-19) diagnostics. Furthermore, Michael Messenger is or has been a paid expert advisor to the European Union, including for COVID-19 therapeutics and diagnostic; a seconded, paid, scientific advisor to the UK Department of Health and Social Care to support the COVID-19 testing programme; and a member of the UK Government Advisory Group for Testing.